Aldeyra Therapeutics (ALDX) Total Debt (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported Total Debt for 14 consecutive years, with $30.3 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 100.68% year-over-year to $30.3 million; the trailing twelve-month figure through Mar 2026 stood at $30.3 million (up 100.68% YoY), and the FY2025 full-year result was $30.2 million, up 101.24% from the prior year.
• Total Debt was little changed at $30.3 million in Q1 2026 per ALDX's latest filing, from $30.2 million in the prior quarter.
• Across five years, Total Debt topped out at $30.3 million in Q1 2026 and bottomed at $15.0 million in Q4 2024.
• Historically, Total Debt has averaged $22.7 million across 5 years, with a median of $20.9 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Debt slumped 50.14% in 2024, then soared 101.24% in 2025.
• Over 5 years, Total Debt stood at $15.9 million in 2022, then surged by 89.46% to $30.1 million in 2023, then plunged by 50.14% to $15.0 million in 2024, then jumped by 101.24% to $30.2 million in 2025, then rose by 0.17% to $30.3 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $30.3 million, $30.2 million, and $30.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.